13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Exelixis

    Acronym: 

    Exelixis

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III Tumour Stream Renal
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Renal
    Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A randomised, double-blind, controlled phase III study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated advanced or metastatic renal cell carcinoma of intermediate or poor risk

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Not Yet Recruiting